PM289 Improved Selected Opioid-Related Findings Without Reducing Conditioned Reward in Female Rats
A 2026 rat study reported beneficial pain-response and withdrawal findings with the experimental CB2 agent PM289, but did not find reduced morphine-conditioned reward in the female group. Improved withdrawal-related signs did not establish improvement on every opioid-related outcome.
The experiment used an osteoarthritis model
Both sexes were assessed on tactile and movement-evoked pain, repeated treatment, reward-related behavior and precipitated withdrawal. PM289 alone retained selected effects without detected tolerance during the protocol. Those are animal-model findings, not a clinical cannabis trial.
Combination effects were outcome- and sex-dependent
The combination enhanced analgesic responses and attenuated withdrawal signs, particularly in females. The reported reward comparison remained negative in that group. Reduced physical signs should not be presented as proven reduction in reinforcement or addiction risk.
Biomarker observations remained separate
The study also measured clusterin and receptor-related proteins. Increased plasma clusterin and selected tissue expression do not independently diagnose a use disorder or explain every behavior. A molecule's proposed biomarker role requires evidence for the particular interpretation being made.
Interpreting the evidence
The study supports preserving the positive, null and sex-related comparisons together. It does not establish PM289 as an approved or proven human adjunct, and it provides no basis for assuming that marijuana reproduces this experimental compound's effects.
Related reading: interpreting cannabis tolerance claims.
Research reference
Garcia MM; Paniagua N; Morales P; Rodríguez-Rivera C; Sánchez-Robles EM; Pascual D; Herradón E; Goicoechea C; Jagerovic N; Girón R (2026). PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain. Neuropharmacology. doi:10.1016/j.neuropharm.2026.111090.
This analysis draws on the supplied study abstract.
